

## 32-13779: LILRB2 Human

<b>Format :</b>	The LILRB2 solution (0.5 mg/ml) contains phosphate buffered saline (pH7.4) and 20% glycerol.
<b>Alternative Name :</b>	Leukocyte Immunoglobulin-like Receptor, CD85D, CD85d, CD85 antigen-like family member D, CD85 antigen, ILT-4, ILT4, ILT4CD85d, Ig-like transcript 4, Immunoglobulin-like transcript 4, LILRB2, LIR2, LIR-2, LIR2CD85D, Leukocyte immunoglobulin-like receptor 2, MIR10, MIR-10, MIR10LILRA6, Monocyte/macrophage immunoglobulinlike receptor 10, leukocyte immunoglobulin-like receptor subfamily B member 2, leukocyte immunoglobulin-like receptor subfamily B member 2 soluble isoform 1.

### Description

Source: HEK293 Cells.

Physical Appearance: Sterile filtered colorless solution.

Biological Activity: null

Leukocyte Immunoglobulin Like Receptor B2 (LILRB2) is a member of the leukocyte immunoglobulin-like receptor (LIR) family. LILRB2 is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. LILRB2 controls inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. LILRB2 competes with CD8 alpha for MHC I binding. LILRB2 binds to classical MHC I proteins as well as the non-classical HLA-G1 and HLA-F molecules.

LILRB2 Human Recombinant produced in HEK293 Cells is a single, glycosylated polypeptide chain containing 444 amino acids (24-461 a.a) and having a molecular mass of 48.3 kDa. LILRB2 is expressed with a 6 amino acid His tag at C-terminus and purified by proprietary chromatographic techniques.

### Product Info

<b>Amount :</b>	10 µg / 2 µg
<b>Purification :</b>	Greater than 95.0% as determined by SDS-PAGE.
<b>Storage condition :</b>	Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles.
<b>Amino Acid :</b>	GTIPKPTLWA EPDSVITQGS PVTLSQCGSL EAQEYRLYRE KKSASWITRI RPELVKNGQF HIPSITWEHT GRYGCQYYSR ARWSELSDPL VLVMTGAYPK PTLAQPSPV VTSGGRVTLQ CESQVAFGGF ILCKEGEDEH PQCLNSQPHA RGSSRAIFSV GPVSPNRRWS HRCYGYDLNS PYVWSSPSDL LELLVPGVSK KPSLSVQPGP VMAPGESLTL QCVSDVG YDR FVLYKEGERD LRQLPGRQPQ AGLSQANFTL GPVRSYGGQ YRCYGAHNLS SECSAPSDPL DILITGQIRG TPFISVQPGP TVASGENVTL LCQSWRQFHT FLLTKAGAAD APLRLRSIHE YPKYQAEFPM SPVTSAHAGT YRCYGLNSD PYLLSHPSEP LELVVGPSM GSSPPPTGPI STPAGPEDQP LTPTGSDPQS GLGRHLGVHH HHHH